Invega Sustenna is a long-acting injectable antipsychotic used to treat schizophrenia and schizoaffective disorder in adults. It contains paliperidone palmitate, a medication that slowly releases into the body over the course of a month, eliminating the need for daily pills. It’s given as an injection once every four weeks after an initial loading phase.
Conditions It Treats
Invega Sustenna is FDA-approved for two conditions. The first is schizophrenia, a chronic mental health condition that can cause hallucinations, delusions, disorganized thinking, and social withdrawal. The second is schizoaffective disorder, which combines symptoms of schizophrenia with mood episodes like depression or mania. Both conditions typically require long-term treatment, and the monthly injection format is specifically designed to support consistent, uninterrupted medication levels in the body.
It is not approved for treating psychosis related to dementia. The FDA requires a boxed warning (the most serious type) stating that elderly patients with dementia-related psychosis who take antipsychotic drugs face a higher risk of death. In clinical trials of similar medications, the death rate among drug-treated elderly patients with dementia was about 4.5% over 10 weeks, compared to 2.6% in those receiving a placebo. Most of these deaths were cardiovascular or infection-related.
How It Works in the Brain
Schizophrenia and schizoaffective disorder involve disrupted signaling between brain cells, particularly in systems that use the chemical messengers dopamine and serotonin. Invega Sustenna works primarily by blocking two types of receptors: dopamine D2 receptors and serotonin 5HT2A receptors. Overactivity at dopamine receptors is closely linked to psychotic symptoms like hallucinations and paranoid thinking, so dampening that signal helps reduce those experiences. Blocking certain serotonin receptors may help with mood symptoms and can offset some of the side effects of dopamine blockade.
Paliperidone also has some activity at receptors involved in blood pressure regulation and histamine signaling, which explains why some people experience side effects like drowsiness or dizziness. It does not interact with the receptors that control bladder function or heart rate in the way some older antipsychotics do, which gives it a somewhat different side effect profile.
Why a Monthly Injection Instead of a Pill
The biggest practical advantage of Invega Sustenna is that it replaces daily oral medication with a single injection each month. This matters because consistency is one of the most important factors in managing schizophrenia. Missing doses of oral antipsychotics, even for a few days, can trigger a relapse of psychotic symptoms. With a long-acting injectable, the medication slowly dissolves from the injection site into the bloodstream over weeks, maintaining steady drug levels without requiring the person to remember a daily pill.
The American Psychiatric Association notes that long-acting injectables have traditionally been offered mainly to people who struggle with taking medications consistently. However, the APA’s position is shifting: these formulations should be discussed with all patients as a valid option, not just those with adherence problems. Some people simply prefer the convenience of a monthly injection over daily pills, and emerging evidence suggests that starting a long-acting injectable early in the course of illness may reduce the risk of relapse and improve long-term outcomes.
What the Injection Schedule Looks Like
Treatment starts with two loading doses designed to build up drug levels quickly. The first injection (234 mg) is given on day one, and the second (156 mg) is given one week later. Both of these initial shots go into the deltoid muscle of the upper arm. After that, you switch to a once-monthly maintenance dose, which can be given in either the upper arm or the gluteal muscle.
The standard monthly maintenance dose is 117 mg, but your prescriber can adjust it anywhere from 39 mg to 234 mg depending on how well you respond and what side effects you experience. After a single injection, the medication reaches peak blood levels somewhere between 7 and 29 days later, depending on the dose and injection site. Deltoid injections tend to produce peak levels a bit faster than gluteal injections. The drug remains detectable in the bloodstream for months after even a single dose, which provides a buffer if an appointment is slightly delayed, though sticking to the monthly schedule is important for consistent symptom control.
What to Expect During Treatment
Most people notice a reduction in psychotic symptoms within the first few weeks, though it can take longer for the full effect to develop. Because the medication is released gradually, you won’t feel a sudden “hit” the way you might with an oral dose. The trade-off is that if you do experience a side effect, it can take longer to clear your system than it would with a pill you simply stop taking.
Common side effects include injection site reactions (pain, redness, or swelling at the spot where the shot was given), drowsiness, weight gain, and restlessness. Some people experience elevated levels of the hormone prolactin, which can affect menstrual cycles or cause breast tenderness. Dizziness when standing up, particularly during the first few doses, is also relatively common due to the medication’s effects on blood pressure regulation.
Because each injection visit is also a point of contact with a healthcare provider, the monthly schedule creates a built-in check-in that can be useful for monitoring symptoms, adjusting the dose, and catching side effects early. For people who find the monthly schedule still burdensome, a related formulation (Invega Trinza) extends the interval to once every three months, though it’s only available after you’ve been stable on Invega Sustenna for at least four months.